Mahfouz Reham A, Hanno Azza G, Rahman Amina M Abd El
Department of Pediatric Dentistry, Faculty of Dentistry, Alexandria University, El Khartoum Square, Alexandria, 21131, Egypt.
Clin Oral Investig. 2025 May 8;29(6):290. doi: 10.1007/s00784-025-06352-y.
This study aimed to evaluate the effectiveness of zirconia-reinforced glass ionomer (ZrGI), in reducing pain and sensitivity, and to assess its clinical success in comparison to glass-hybrid glass ionomer (GhGI) in hypomineralized permanent first molars (HPFM) following the Atraumatic Restorative Treatment (ART) approach.
This randomized controlled clinical trial included 7-10-year-old children. Eighty-eight HPFMs with evidence of caries, with or without hypersensitivity were included. These molars scored (2a), (2b), (4a), or (4b) according to the MIH Treatment Need Index (MIH-TNI). Selective caries removal was performed using the ART protocol. The test group received ZrGI (Zirconomer®) restorations, and the control group received GhGI (Equia Forte®) restorations. Pain and sensitivity were assessed pre-operatively, using the Visual Analogue Scale (VAS), then re-assessed post-operatively after 1 week and after 3,6,9, and 12 months (M). Clinical success was evaluated, starting from the 3-month visit, using the ART evaluation criteria.
After 12M, the median pain scores for the ZrGI gp., (Q1-Q3; 0.00 - 0.00) and GhGI gp., (Q1-Q3; 0.00 - 0.00) showed no statistically significant difference, (p = 0.329). Median sensitivity scores for the ZrGI gp., (Q1-Q3; 0.00 - 5.00) and the GhGI gp., (Q1-Q3;0.00 - 3.50), also showed no statistically significant difference, (p = 0.344). No significant difference was found between the 12M success rate of ZrGI (86.4%) and GhGI (84.1%), (p = 0.765).
Regarding the reduction of pain and sensitivity, and clinical success, zirconia-reinforced GIC was as effective as glass hybrid GIC in restoring HPFM, using the ART approach.
Zirconia-reinforced glass ionomer cement may be a promising restorative material due to its favorable physical properties and acceptable clinical results, as shown in this study. It may be used as an interim restoration in hypomineralized permanent first molars and holds potential for even wider applications in clinical pediatric dentistry.
Please refer to this study by its ClinicalTrials.gov identifier: NCT05494749.
本研究旨在评估氧化锆增强玻璃离子(ZrGI)在减轻疼痛和敏感方面的有效性,并与玻璃混合玻璃离子(GhGI)相比,评估其在非创伤性修复治疗(ART)方法下对低矿化恒第一磨牙(HPFM)的临床成功率。
这项随机对照临床试验纳入了7至10岁的儿童。纳入了88颗有龋病证据、有或无敏感症状的HPFM。根据MIH治疗需求指数(MIH-TNI),这些磨牙的评分为(2a)、(2b)、(4a)或(4b)。使用ART方案进行选择性龋病去除。试验组接受ZrGI(Zirconomer®)修复体,对照组接受GhGI(Equia Forte®)修复体。术前使用视觉模拟量表(VAS)评估疼痛和敏感情况,然后在术后1周以及术后3、6、9和12个月(M)进行重新评估。从3个月随访开始,使用ART评估标准评估临床成功率。
12个月后,ZrGI组的中位疼痛评分(Q1-Q3;0.00 - 0.00)和GhGI组的中位疼痛评分(Q1-Q3;0.00 - 0.00)无统计学显著差异(p = 0.329)。ZrGI组的中位敏感评分(Q1-Q3;0.00 - 5.00)和GhGI组的中位敏感评分(Q1-Q3;0.00 - 3.50)也无统计学显著差异(p = 0.344)。ZrGI(86.4%)和GhGI(84.1%)的12个月成功率之间未发现显著差异(p = 0.765)。
在减轻疼痛和敏感以及临床成功率方面,使用ART方法时,氧化锆增强玻璃离子水门汀在修复HPFM方面与玻璃混合玻璃离子水门汀一样有效。
如本研究所示,氧化锆增强玻璃离子水门汀因其良好的物理性能和可接受的临床结果,可能是一种有前景的修复材料。它可作为低矿化恒第一磨牙的临时修复材料,在临床儿童牙科中具有更广泛应用的潜力。
请通过其ClinicalTrials.gov标识符:NCT05494749查阅本研究。